

Figure S1. Overall survival in patients with low and high levels of Siglec-7 expression. (A) There was a significant difference in overall survival between HLA-A*24:02-matched and -unmatched patients with low levels of Siglec-7 expression in the tumor microenvironment ($P=0.041$). (B) There was no significant difference in overall survival between HLA-A*24:02-matched and -unmatched patients with high levels of Siglec-7 expression. Siglec-7, sialic acid-binding immunoglobulin-like lectin 7; HLA, human leukocyte antigen.




Figure S2. Relationship of CD68 expression and prognosis with Siglec-7 expression. (A) A scatterplot for CD68 and Siglec-7 is shown. The values were transformed by \log_{10} . There was a strong correlation between the levels of Siglec-7 and CD68 expressions in tumor tissue ($P < 0.001$). (B) A Kaplan-Meier curve for overall survival according to the levels of CD68 expression is shown. The optimal cut-off value was determined as 0.562 using ROC curve analysis at 36 months. There was no significant difference in overall survival between patients with high and low levels of CD68 expression ($P = 0.528$). Siglec-7, sialic acid-binding immunoglobulin-like lectin 7.




Figure S3. Tumor-infiltrating lymphocytes (TILs) in tumor tissues with high and low Siglec-7 expression. Representative IHC images of CD3 and CD8 in CRC tissues with high and low expression levels of Siglec-7. The upper row represents high CD3⁺ and CD8⁺ cell densities; the lower row represents low CD3⁺ and CD8⁺ cell densities. Scale bar, 100 μ m. (A) In CRC tissues with high expression levels of Siglec-7, both high and low densities of CD3⁺ and CD8⁺ cells were observed. (B) In CRC tissues with low expression levels of Siglec-7, both high and low densities of CD3⁺ and CD8⁺ cells were observed. Siglec-7, sialic acid-binding immunoglobulin-like lectin 7; IHC, immunohistochemistry; CRC, colorectal cancer.

